Aadi Bioscience, Inc.

As of September 11, 2025, Aadi Bioscience, Inc. shows a neutral trend with mixed technical signals, having underperformed the S&P 500 year-to-date but outperformed it over the past month, suggesting a cautious investment approach.

As of May 8, 2025, Aadi Bioscience, Inc. is considered an attractive investment due to its undervalued status with a P/E ratio of 3, a Price to Book Value of 0.40, and a high ROCE of 648.45%, despite a year-to-date stock decline of 38.19%, indicating significant growth potential compared to its peers.

As of June 17, 2025, the market trend is neutral with mixed indicators, showing mildly bullish signals from the weekly MACD and KST, but mildly bearish sentiment from daily moving averages and Bollinger Bands, resulting in no clear direction from the RSI.

Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing treatments for ocular diseases and diabetic complications. As of March 2025, it reported net sales of $7 million and a net profit of $73 million, with a market cap of $94.69 million.

As of Jun 18, Aadi Bioscience, Inc. has a market capitalization of 94.69 million and net sales of 27.77 million with a net profit of 27.62 million over the latest four quarters. As of Dec 24, shareholder's funds are 52.48 million and total assets are 70.71 million.